Hermetica Superfood Encyclopedia
The Short Answer
Neonothopanus nambi produces aurisin A, a bioactive compound demonstrating antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) at a minimum inhibitory concentration of 7.81 μg/mL, alongside chloroform mycelial fractions that inhibit nitric oxide production in LPS-stimulated macrophages with an IC50 of 10.9 μg/mL. The ethyl acetate culture filtrate fraction exhibits a MIC/MBC of 2–16 μg/mL against S. aureus ATCC 25923, approaching the potency of vancomycin (0.5–1 μg/mL), representing its most clinically significant preclinical antibacterial finding to date.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordNeonothopanus nambi bioactivity
Neonothopanus nambi — botanical close-up
Health Benefits
**Anti-MRSA Antibacterial Activity**: Aurisin A isolated from N
nambi demonstrates a MIC of 7.81 μg/mL against MRSA strains ATCC 33591 and ATCC 43300, suggesting potential utility against antibiotic-resistant Gram-positive bacterial infections. The ethyl acetate culture filtrate fraction further exhibits MIC/MBC values of 2–4 μg/mL against S. aureus, nearing the efficacy of clinical vancomycin.
**Anti-Inflammatory Effects**
The chloroform mycelial fraction inhibits lipopolysaccharide-induced nitric oxide production in RAW264.7 macrophages with an IC50 of 10.9 μg/mL, comparable to the reference inhibitor L-NAME (IC50 10.2 μg/mL). This activity suggests possible suppression of iNOS and COX-2 pathways, though direct gene expression confirmation remains unpublished.
**Antiparasitic and Nematicidal Properties**: Culture filtrate of N
nambi kills root-knot nematode (Meloidogyne incognita) larvae in vitro at concentrations of 50–100 mg/L, with field trials showing reduction of root gall formation when 30 mL filtrate and 30 g spawn are applied per pot. Notably, bioactive doses appear selective, sparing beneficial non-target nematode species.
**Potential Anti-Mycobacterial Activity**
Aurisin A and aurisin K, both isolated metabolites from N. nambi, have been investigated for activity against Mycobacterium tuberculosis, positioning this fungus as a candidate for anti-tuberculosis lead compound discovery. Specific MIC values against M. tuberculosis strains require further publication and independent confirmation.
**Potential Anti-Plasmodial Activity**
Aurisins A and K have been noted for anti-Plasmodium bioactivity, suggesting possible antimalarial applications in the early-stage drug discovery pipeline. These effects remain at the level of preliminary in vitro screening without confirmed mechanism or in vivo validation.
**Nitric Oxide Pathway Modulation**: Multiple solvent fractions of N
nambi extracts show graded inhibition of NO production in macrophage cell lines, with IC50 values ranging from 10.9 to 64.6 μg/mL depending on fraction polarity. This gradient of activity across hexane, chloroform, and ethyl acetate fractions suggests multiple chemical classes contributing to anti-inflammatory bioactivity.
**Biofilm-Associated Antibacterial Effects**
Aurisin A's activity against established MRSA strains including biofilm-forming isolates (ATCC 33591 and 43300) implies a potential role in disrupting or preventing biofilm formation, a critical virulence mechanism in hospital-acquired staphylococcal infections. Mechanistic elucidation of cell wall or membrane targeting is ongoing.
Origin & History
Natural habitat
Neonothopanus nambi is a bioluminescent basidiomycete fungus native to tropical and subtropical regions of Asia, Africa, and the Americas, typically found growing on decaying wood and leaf litter in humid forest environments. It belongs to the family Omphalotaceae and produces a faint green bioluminescence attributed to a fungal luciferin-luciferase biochemical system. The species has been cultivated under laboratory conditions since approximately 2010 for research purposes, with mycelia grown in liquid culture media and culture filtrates harvested for bioactive extraction.
“Neonothopanus nambi has no documented history of use in any traditional medicine system, including Ayurveda, Traditional Chinese Medicine, African ethnobotany, or indigenous American healing practices, and no food use records have been identified. Research into its bioactive properties is a product of contemporary natural products chemistry and began in earnest around 2010, driven primarily by interest in its bioluminescent properties and secondary metabolite diversity. Its close relative Neonothopanus gardneri, a Brazilian bioluminescent species, has similarly attracted scientific attention for secondary metabolites but shares the absence of ethnomedical documentation. The species' cultural significance is thus entirely confined to modern mycological and pharmacognostic research communities, with no folklore, ritual, or culinary traditions associated with its use.”Traditional Medicine
Scientific Research
All existing evidence for N. nambi bioactivity derives exclusively from in vitro laboratory studies, with no published animal (in vivo) studies or human clinical trials identified as of the available research record. Published work has quantified antibacterial MIC/MBC values for crude solvent fractions and isolated aurisin A against S. aureus and MRSA strains, anti-inflammatory IC50 values in RAW264.7 macrophage cell lines, and nematicidal larval kill rates in controlled pot experiments against M. incognita. No sample sizes for replicate experiments, confidence intervals, or statistical analyses have been reported in available summaries, limiting the interpretability of the reported IC50 and MIC values. The evidence base is nascent and exploratory, characteristic of early-phase natural product discovery research, and independent replication of all reported bioactivities has not been confirmed.
Preparation & Dosage
Traditional preparation
**Laboratory Liquid Culture Extract (Research Use Only)**
25 mg/L (CHCl3) to 6,035 mg/L (H2O) from culture filtrate
Mycelia and culture filtrates are partitioned sequentially with n-hexane, chloroform (CHCl3), ethyl acetate (EtOAc), and water; yields range from . No standardized commercial preparation exists.
**Research Assay Concentrations**
Bioactive fractions dissolved in 10% DMSO are tested at 0.5–1,024 μg/mL in broth microdilution antibacterial assays; anti-inflammatory assays use 10–100 μg/mL on RAW264.7 cells.
**Nematicidal Field Application (Experimental)**
30 mL per pot combined with 30 g spawn per pot has been used in controlled nematode management studies; this is not an established agricultural product dose
Culture filtrate applied at .
**No Established Human Supplemental Dose**
No recommended dietary allowance, therapeutic dose, or standardized supplement form (capsule, powder, tincture) has been established; N. nambi is not commercially available as a nutritional supplement as of current evidence.
**Timing and Formulation Notes**
All active fractions in research settings require solvent-based preparation; direct oral bioavailability of aurisin A or other active metabolites is entirely unstudied and unknown.
Nutritional Profile
No nutritional composition data—including macronutrient (protein, carbohydrate, lipid), micronutrient (vitamins, minerals), or dietary fiber content—have been reported for Neonothopanus nambi fruiting bodies or mycelia in the available scientific literature. Unlike edible and medicinally cultivated mushrooms such as Lentinula edodes or Grifola frondosa, N. nambi has not been characterized for beta-glucan content, ergosterol, or polysaccharide fractions. The bioactive chemical constituents identified to date are secondary metabolites including aurisin A and aurisin K, with additional uncharacterized compounds across hexane, chloroform, ethyl acetate, and aqueous fractions likely including alkaloids, tannins, and possibly depsides analogous to related Omphalotaceae species. Bioavailability of any constituent following oral ingestion is entirely unstudied.
How It Works
Mechanism of Action
The antibacterial mechanism of aurisin A and related fractions from N. nambi is hypothesized to involve disruption of Gram-positive bacterial cell walls or plasma membranes, consistent with its selective activity against S. aureus and MRSA and complete inactivity against Gram-negative E. coli, which possesses an additional outer membrane barrier. The anti-inflammatory activity of the chloroform mycelial fraction is proposed to operate through suppression of inducible nitric oxide synthase (iNOS) and potentially cyclooxygenase-2 (COX-2) gene expression in activated macrophages, thereby reducing LPS-stimulated nitric oxide output to levels comparable to the selective iNOS inhibitor L-NAME. Antiparasitic effects on Meloidogyne incognita larvae are mechanistically uncharacterized but may involve cuticle disruption or neurotoxic action similar to other fungal nematicidal agents. Anti-mycobacterial and anti-plasmodial effects of aurisins A and K lack elucidated molecular targets, and full mechanistic studies using transcriptomic, proteomic, or biochemical target-identification approaches have not yet been published.
Clinical Evidence
No clinical trials involving human participants have been conducted with Neonothopanus nambi extracts, isolated aurisins, or any derived formulation. All efficacy data originate from cell-free microbial susceptibility testing and cellular assays using murine macrophage lines, which cannot be extrapolated to human pharmacokinetics, efficacy, or safety without bridging in vivo studies. The preclinical in vitro outcomes—particularly aurisin A's MIC of 7.81 μg/mL against MRSA and CHCl3 fraction IC50 of 10.9 μg/mL for NO inhibition—are scientifically interesting but represent very early-stage signals with low confidence for predicting clinical benefit. Translation to therapeutic application would require toxicology studies, pharmacokinetic profiling, in vivo disease model validation, and eventual phase I–III clinical trial programs before any clinical conclusions can be drawn.
Safety & Interactions
Neonothopanus nambi extracts exhibit cytotoxicity toward RAW264.7 murine macrophages at concentrations of 10–100 μg/mL in vitro, indicating a narrow therapeutic window between anti-inflammatory efficacy (IC50 10.9 μg/mL) and cellular toxicity, which is a significant preclinical safety concern. No in vivo toxicology studies, maximum tolerated dose data, genotoxicity assays, or organ-specific toxicity profiles have been published for any extract or isolated compound from this species. No drug interaction data exist; theoretical interactions with anti-inflammatory agents such as indomethacin, iNOS inhibitors, or antibiotics like vancomycin are plausible based on overlapping mechanisms but are entirely unstudied. Neonothopanus nambi cannot be recommended for human consumption, supplementation, or self-medication in any form; pregnant and lactating individuals should avoid all contact with experimental fungal extracts lacking safety characterization.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Neonothopanus nambi (Neonothopanus nambi (Jungh.) Henn.)N. nambinambi ghost mushroomNeonothopanus nambiOmphalotaceae bioluminescent fungus
Frequently Asked Questions
What is aurisin A and what does it do in Neonothopanus nambi research?
Aurisin A is a secondary metabolite isolated from Neonothopanus nambi that demonstrates antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration of 7.81 μg/mL against ATCC 33591 and ATCC 43300 strains. It has also been investigated for activity against Mycobacterium tuberculosis and Plasmodium species, though specific MIC values and mechanisms for these pathogens remain unpublished. All data are currently from in vitro studies only, and aurisin A has not been tested in humans.
Is Neonothopanus nambi safe to consume or use as a supplement?
Neonothopanus nambi is not safe to use as a supplement and is not available in any commercial supplement form; it is a research-stage organism only. In vitro studies have shown cytotoxicity to macrophage cell lines at concentrations of 10–100 μg/mL, overlapping with its biologically active dose range, indicating a narrow safety margin. No human toxicology, pharmacokinetic, or clinical safety data exist for any extract or compound derived from this fungus.
Does Neonothopanus nambi have any proven anti-inflammatory effects?
Preclinical in vitro evidence shows that the chloroform mycelial fraction of N. nambi inhibits nitric oxide production in LPS-stimulated RAW264.7 macrophages with an IC50 of 10.9 μg/mL, comparable to reference inhibitor L-NAME (IC50 10.2 μg/mL) and indomethacin (16.6 μg/mL). This suggests suppression of iNOS and possibly COX-2 pathways, though direct gene expression confirmation has not been published. These findings have no clinical validation and cannot be translated to human therapeutic recommendations.
Can Neonothopanus nambi be used for nematode or pest control?
Experimental evidence indicates that culture filtrate of N. nambi kills Meloidogyne incognita (root-knot nematode) larvae in vitro at 50–100 mg/L and reduces root gall formation in pot studies when applied at 30 mL filtrate plus 30 g spawn per pot. The bioactive effect appears selective, with non-target beneficial nematodes reportedly unaffected at active doses, making it a potential biological control candidate. However, this application remains experimental and is not an approved or commercially available biocontrol product.
Are there any clinical trials for Neonothopanus nambi?
No human clinical trials have been conducted with Neonothopanus nambi, its extracts, or any isolated compound such as aurisin A or aurisin K as of the available research record. All published bioactivity data come from in vitro microbial susceptibility tests and cell culture assays; no animal in vivo studies, pharmacokinetic data, or phase I–III trials have been reported. The compound is at the earliest stage of natural product discovery and would require extensive preclinical development before human trials could be considered.
How does Neonothopanus nambi compare to vancomycin in treating antibiotic-resistant bacteria?
Neonothopanus nambi's aurisin A compound and ethyl acetate culture filtrate show MIC/MBC values of 2–4 μg/mL against S. aureus, approaching the efficacy of clinical vancomycin, making it a promising candidate for MRSA infections. However, vancomycin remains the established clinical standard with decades of safety and efficacy data, while N. nambi research is still in early stages. The mushroom extract may offer an alternative research avenue for overcoming antibiotic resistance, but further human trials are needed before clinical comparison can be made.
What is the current research status on Neonothopanus nambi's effectiveness against MRSA?
In vitro studies demonstrate that aurisin A from N. nambi achieves a minimum inhibitory concentration (MIC) of 7.81 μg/mL against MRSA strains ATCC 33591 and ATCC 43300, with the ethyl acetate culture filtrate fraction showing even stronger activity at 2–4 μg/mL. These laboratory results are promising for antibiotic-resistant Gram-positive bacterial infections, but translation to human clinical efficacy remains unproven. Most research to date has been conducted in controlled laboratory settings rather than in vivo or clinical trial environments.
Who might benefit most from Neonothopanus nambi supplementation based on current research?
Current evidence suggests potential benefit for individuals concerned with antibiotic-resistant bacterial infections, particularly MRSA, though this remains experimental and not yet established for human supplementation. People with chronic infections resistant to conventional antibiotics or those seeking natural antimicrobial compounds may be interested in emerging research on N. nambi. However, no specific patient populations have been identified in clinical trials, and supplementation should not replace established medical treatments for serious bacterial infections.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w neonothopanus-nambi-neonothopanus-nambi curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
